Agenus Inc. (AGEN)

Market Cap	299.87M
Revenue (ttm)	161.42M
Net Income (ttm)	-239.61M
Shares Out	21.00M
EPS (ttm)	-12.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	668,628
Open	16.57
Previous Close	16.69
Day's Range	14.20 - 16.59
52-Week Range	4.78 - 38.60
Beta	1.35
Analysts	Strong Buy
Price Target	102.00 (+614.29%)
Earnings Date	Aug 6, 2024

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN

Financial Performance

In 2023, Agenus's revenue was $156.31 million, an increase of 59.47% compared to the previous year's $98.02 million. Losses were -$245.97 million, 11.7% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price forecast is $102.0, which is an increase of 614.29% from the latest price.

Price Target

$102.0

(614.29% upside)

Analyst Consensus: Strong Buy